Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the current earnings call transcript. Focus is on debt reduction: targeted debt reduction of about Rs. 700 crores between Strides and OneSource. Net debt to EBITDA ratio has improved significantly (from ~8x in FY22 to about 3.3x in H1 FY24), with a target to reduce it below 3 in FY24. Emphasis on free cash generation, reducing cash-to-cash cycle, and improving operating efficiency to manage working capital and debt. Management focuses on consolidation and debt reduction over the next 2-3 quarters rather than inorganic growth

Any current/future capex/capital investment/strategic investment?

Strides Pharma is continuing to invest in CAPEX for ongoing needs in India and the US despite net debt reduction efforts. Network optimization program has been completed, including mothballing the Singapore facility and shifting production to Chestnut Ridge, US. The company is focusing on building its CDMO business (OneSource) with detailed plans for growth to $160 million in launch year and $400 million by FY27. No explicit mention of new large-scale strategic or inorganic investments for Strides; focus remains on consolidation, debt reduction, and organic growth. Arun Kumar indicated

Future growth expectations in sales/revenue/volumes?

US business targeted to reach $400 million in sales within 2 financial years, maintaining margin profile (Page 8, 9). New product launches expected to be significant drivers, with 3-4 products having $20 million+ exit run rates by year-end (Page 8). Other regulated markets to grow as mirrored markets to the US; expected to reach similar size in about 4 to 4.5 years, with current run rate around $200 million (Page 10). Growth markets and access markets anticipated to become equally important in next 2-3 years (Page 5). CDMO business (OneSource) projected to hit approximately $160 million in lau

Future growth expectations in earnings/operating earnings/profits/EPS?

Strides targets $400 million revenue in US business within 2 years while maintaining current margin profiles. US growth driven by high-value product launches, with 3-4 products expected to hit $20 million+ exit run rates by year-end. Other regulated markets aimed to mirror US market size (~$400 million), expected over 4 to 4.5 years. EBITDA expected around Rs. 950 crores next year despite divestment of Rs. 150 crores EBITDA to OneSource. Focus on stable operating expenses (~$200 million annually) to boost EBITDA and PAT margins. Network optimization and asset sales improve EBITDA and earnings

Strides PharmaQ2 FY24Pharmaceuticals & Biotechnology

Strides Pharma Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,183P/E: 18.8Market Cap: ₹10.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

US business targeted to reach $400 million in sales within 2 financial years, maintaining margin profile (Page 8, 9).
New product launches expected to be significant drivers, with 3-4 products having $20 million+ exit run rates by year-end (Page 8).
Other regulated markets to grow as mirrored markets to the US; expected to reach similar size in about 4 to 4.5 years, with current run rate around $200 million (Page 10).
Growth markets and access markets anticipated to become equally important in next 2-3 years (Page 5).
CDMO business (OneSource) projected to hit approximately $160 million in launch year and $400 million by FY27 (Page 11).
Overall company revenue growth targeted at around 15-16%, with stronger H2 performance expected (Page 5).

Margin guidance

Category 3

Strides targets $400 million revenue in US business within 2 years while maintaining current margin profiles.
US growth driven by high-value product launches, with 3-4 products expected to hit $20 million+ exit run rates by year-end.
Other regulated markets aimed to mirror US market size (~$400 million), expected over 4 to 4.5 years.
EBITDA expected around Rs. 950 crores next year despite divestment of Rs. 150 crores EBITDA to OneSource.
Focus on stable operating expenses (~$200 million annually) to boost EBITDA and PAT margins.
Network optimization and asset sales improve EBITDA and earnings flow-through by about Rs. 60 crores annually.
Margin improvements from restructuring and mothballing of less viable facilities support EPS growth.
Anticipated strong free cash flow generation aiding debt reduction and enhancing PAT conversion.
Growth markets expected to become as important as regulated markets in 2-3 years, providing additional earnings potential.

See what Strides Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any new fundraising through debt or equity in the current earnings call transcript.
Focus is on debt reduction: targeted debt reduction of about Rs. 700 crores between Strides and OneSource.
Net debt to EBITDA ratio has improved significantly (from ~8x in FY22 to about 3.3x in H1 FY24), with a target to reduce it below 3 in FY24.
Emphasis on free cash generation, reducing cash-to-cash cycle, and improving operating efficiency to manage working capital and debt.
Management focuses on consolidation and debt reduction over the next 2-3 quarters rather than inorganic growth or raising new funds.
No immediate plans for significant inorganic growth or capital raising; preference is consolidating existing operations and improving financial health.

Order book

Yes

- The company reported a strong order book in H2 FY24 with several product approvals recently received, including a critical product and generic Vascepa. - There is a large order book for contract manufacturing opportunities led by GLP in OneSource. - The CDMO business OneSource has a backlog driven by approximately 14-15 customers with a peak revenue potential of about $300 million in GLP programs, contingent on regulatory approvals and market access. - The company has significant R&D income from development and filing batches for customers, with commercial supplies expected to start gradually around FY25 and main patterns extending to 2030. - The ongoing product approvals and site changes (from Chestnut Ridge to India) are intended to enhance competitiveness and manufacturing robustness. Overall, the order book is healthy with strong visibility on contracts and expected growth through regulatory approvals and market launches.

See what Strides Pharma management said on order book — free account, 30 seconds.

Capex plans

Strides Pharma is continuing to invest in CAPEX for ongoing needs in India and the US despite net debt reduction efforts.
Network optimization program has been completed, including mothballing the Singapore facility and shifting production to Chestnut Ridge, US.
The company is focusing on building its CDMO business (OneSource) with detailed plans for growth to $160 million in launch year and $400 million by FY27.
No explicit mention of new large-scale strategic or inorganic investments for Strides; focus remains on consolidation, debt reduction, and organic growth.
Arun Kumar indicated for the next 2-3 quarters, the priority is improving cash-to-cash cycle and reducing debt; no inorganic growth planned for Strides during this period.
CAPEX efforts support competitive positioning, manufacturing robustness, and product approvals, especially for US and other regulated markets.

Track Strides Pharma — get its next earnings analysis in your feed

Margin guidance

Category 3

Strides targets $400 million revenue in US business within 2 years while maintaining current margin profiles.
US growth driven by high-value product launches, with 3-4 products expected to hit $20 million+ exit run rates by year-end.
Other regulated markets aimed to mirror US market size (~$400 million), expected over 4 to 4.5 years.
EBITDA expected around Rs. 950 crores next year despite divestment of Rs. 150 crores EBITDA to OneSource.
Focus on stable operating expenses (~$200 million annually) to boost EBITDA and PAT margins.
Network optimization and asset sales improve EBITDA and earnings flow-through by about Rs. 60 crores annually.
Margin improvements from restructuring and mothballing of less viable facilities support EPS growth.
Anticipated strong free cash flow generation aiding debt reduction and enhancing PAT conversion.
Growth markets expected to become as important as regulated markets in 2-3 years, providing additional earnings potential.

Order book

Yes

How does Strides Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisStrides Pharma

Rev 3Mar 3

See where Strides Pharma sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Strides Pharma rank in Pharmaceuticals & Biotechnology?

Compare Strides Pharma against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Strides Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Ind-Swift Labs. (Q1 FY27)
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Strides Pharma Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Margin guidance

Order book

How does Strides Pharma rank in Pharmaceuticals & Biotechnology?

Continue your research

What Strides Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season